Company intelligence / Profile preview

Helomics

Pittsburgh, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Helomics provided personalized tumor profiling and diagnostic services to support clinical oncology decision-making, leveraging live and fixed cell analyses plus bioinformatics and AI/ML for more tailored cancer therapies[1].

Therapeutic areas: Oncology
Modalities: Diagnostics (including next-generation sequencing, immunoassays, live and fixed cellular analysis)Artificial intelligence/machine learning–enhanced drug discovery
Industry: Molecular Diagnostics

Partnerships

Predictive Oncology (parent/strategic integrator)Individumed (biomarker development and cancer biospecimen analytics)[5]

Beyond the preview

Go deeper on Helomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Helomics.

Explore the full profile